Scientists at CSIRO's Australian Animal Health Laboratory (AAHL) in Geelong have launched a potentially revolutionary research project aimed at reducing the threat of the lethal H5N1 avian influenza virus.

US company Dharmacon, now part of Thermo Fisher Scientific, achieved a major breakthrough in RNAi technology by reducing off-target events.

When Merck announced last year it was buying Sirna Therapeutics for over US$1 billion, the world sat up and took notice. RNAi was now being seen as not only a revolution in our understanding but something with an unimaginable dollar value as well.

Everyone is excited about the use of RNAi in the laboratory, but some are now taking the next step and looking at its use in vivo.

Could a targeted therapy to activate the endonuclease Drosha in tumour cells force them to differentiate and die?

MicroRNAs play a role in the immune response to antigens, a new study has found.